Approximations of the target-mediated drug disposition model and identifiability of model parameters
- PMID: 19005743
- DOI: 10.1007/s10928-008-9102-8
Approximations of the target-mediated drug disposition model and identifiability of model parameters
Abstract
Models for drugs exhibiting target-mediated drug disposition (TMDD) play an important role in the investigation of biological products (Mager and Jusko 2001). These models are often overparameterized and difficult to converge. A simpler quasi-equilibrium (QE) approximation of the general model has been suggested (Mager and Krzyzanski 2005), but even this simpler form can be overparameterized when, for example, drug target level is not available. This work (a) introduces quasi-steady-state (QSS) and Michaelis-Menten (MM) approximations of the TMDD model, (b) derives the relationships between the parameters of the TMDD, QE, QSS and MM models, (c) investigates the parameter ranges where the simplified approximations are equivalent to the TMDD model, (d) proposes an algorithm for establishing identifiability of these models, and (e) tests this algorithm on simulated datasets. The proposed QSS approximation is more general than the QE approximation: it degenerates into the QE approximation when the internalization rate of the drug-target complex is much smaller than its dissociation rate. The proposed identifiability analysis algorithm may be applied to provide justification for use of simplified approximations, avoiding use of incorrect parameter estimates of over-parameterized TMDD models while simultaneously saving time and resources required for the pharmacokinetics analysis of drugs with TMDD. The utility of the derived approximations and of the identifiability algorithm was demonstrated on the examples of the simulated data sets. The simulation examples indicated that the QSS model may be preferable to the QE model when the internalization rate of the drug-target complex significantly exceeds its dissociation rate. The MM approximation may be adequate when the drug concentration significantly exceeds the target concentrations or when the target occupancy is close to 100%.
Similar articles
-
Target-mediated drug disposition model for drugs with two binding sites that bind to a target with one binding site.J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):463-475. doi: 10.1007/s10928-017-9533-1. Epub 2017 Jul 19. J Pharmacokinet Pharmacodyn. 2017. PMID: 28725976
-
Target-mediated drug disposition model for drugs that bind to more than one target.J Pharmacokinet Pharmacodyn. 2010 Aug;37(4):323-46. doi: 10.1007/s10928-010-9163-3. Epub 2010 Jul 29. J Pharmacokinet Pharmacodyn. 2010. PMID: 20669044
-
Target-mediated drug disposition model for drugs with N > 2 binding sites that bind to a target with one binding site.J Pharmacokinet Pharmacodyn. 2024 Dec;51(6):703-720. doi: 10.1007/s10928-024-09917-8. Epub 2024 Apr 19. J Pharmacokinet Pharmacodyn. 2024. PMID: 38639818
-
Target-mediated drug disposition model: approximations, identifiability of model parameters and applications to the population pharmacokinetic-pharmacodynamic modeling of biologics.Expert Opin Drug Metab Toxicol. 2009 Jul;5(7):803-12. doi: 10.1517/17425250902992901. Expert Opin Drug Metab Toxicol. 2009. PMID: 19505189 Review.
-
Small-Molecule Compounds Exhibiting Target-Mediated Drug Disposition (TMDD): A Minireview.J Clin Pharmacol. 2017 Feb;57(2):137-150. doi: 10.1002/jcph.804. Epub 2016 Sep 6. J Clin Pharmacol. 2017. PMID: 27489162 Review.
Cited by
-
Dynamics of target-mediated drug disposition: characteristic profiles and parameter identification.J Pharmacokinet Pharmacodyn. 2012 Oct;39(5):429-51. doi: 10.1007/s10928-012-9260-6. Epub 2012 Aug 1. J Pharmacokinet Pharmacodyn. 2012. PMID: 22851162 Free PMC article.
-
Clinical Pharmacokinetics and Pharmacodynamics of Biologic Therapeutics for Treatment of Systemic Lupus Erythematosus.Clin Pharmacokinet. 2017 Feb;56(2):107-125. doi: 10.1007/s40262-016-0426-z. Clin Pharmacokinet. 2017. PMID: 27384528 Free PMC article. Review.
-
Population pharmacokinetic analysis of denosumab in patients with bone metastases from solid tumours.Clin Pharmacokinet. 2012 Apr 1;51(4):247-60. doi: 10.2165/11598090-000000000-00000. Clin Pharmacokinet. 2012. PMID: 22420579
-
Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer.Int J Mol Sci. 2020 May 26;21(11):3753. doi: 10.3390/ijms21113753. Int J Mol Sci. 2020. PMID: 32466535 Free PMC article.
-
Target-mediated drug disposition model: relationships with indirect response models and application to population PK-PD analysis.J Pharmacokinet Pharmacodyn. 2009 Aug;36(4):341-51. doi: 10.1007/s10928-009-9125-9. Epub 2009 Jul 4. J Pharmacokinet Pharmacodyn. 2009. PMID: 19578985
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical